NICE recommends approval of Pradaxa for DVT and PE-Boehringer

In draft guidelines, NICE has announced that Pradaxa (dabigatran etexilate), from Boehringer, was cost effective enough to be recommended for approval for Deep Vein Thrombosis and Pulmonary Embolism. NICE has already approved funding for the use of Pradaxa on the NHS in England to prevent Venous Thrombembolic Events in adults who have undergone elective total hip or total knee replacement surgery and for the prevention of stroke and systemic embolism in people with atrial fibrillation.